Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

JNCCN 360

jnccn360.org - By: Sarah Campen, PharmD Posted: Monday, June 22, 2020 Despite the fact that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology provide guidance for discontinuation of tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML), a study presented...

Read the full article here